Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NTRBNASDAQ:VANINASDAQ:XAIRNASDAQ:ZYXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNTRBNutriband$5.64-1.6%$5.80$3.72▼$11.78$62.91M1.1878,599 shs10,366 shsVANIVivani Medical$1.01-3.8%$1.05$0.91▼$2.09$59.84M2.81164,758 shs83,049 shsXAIRBeyond Air$0.18-2.2%$0.24$0.17▼$1.49$15.94M0.251.19 million shs3.36 million shsZYXIZynex$2.10-3.2%$2.62$1.66▼$11.08$63.50M0.7158,812 shs101,601 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNTRBNutriband-1.72%-4.82%+21.40%-19.52%+57.42%VANIVivani Medical+1.94%+1.94%+2.94%-7.08%-43.24%XAIRBeyond Air-3.23%-5.22%-20.11%-48.94%-83.15%ZYXIZynex+0.93%+6.90%-0.46%-70.99%-79.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNTRBNutriband2.7608 of 5 stars3.53.00.00.03.31.70.6VANIVivani Medical3.0323 of 5 stars3.55.00.00.01.83.30.0XAIRBeyond Air4.4335 of 5 stars3.53.00.03.53.32.51.3ZYXIZynex2.6714 of 5 stars3.20.00.00.01.12.53.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNTRBNutriband 3.00Buy$13.00130.50% UpsideVANIVivani Medical 3.00Buy$4.00296.04% UpsideXAIRBeyond Air 3.00Buy$1.50712.57% UpsideZYXIZynex 2.33Hold$6.00185.71% UpsideCurrent Analyst Ratings BreakdownLatest XAIR, NTRB, ZYXI, and VANI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025ZYXIZynexRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.004/30/2025ZYXIZynexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.004/16/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/15/2025ZYXIZynexRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform4/4/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/26/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/13/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/12/2025ZYXIZynexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $15.003/12/2025ZYXIZynexRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$11.00 ➝ $5.503/12/2025ZYXIZynexLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNTRBNutriband$2.14M29.40N/AN/A$0.73 per share7.73VANIVivani MedicalN/AN/AN/AN/A$0.41 per shareN/AXAIRBeyond Air$3.02M5.27N/AN/A$0.27 per share0.68ZYXIZynex$172.40M0.37$0.12 per share18.01$1.36 per share1.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNTRBNutriband-$5.49M-$0.99N/AN/AN/A-338.51%-54.49%-48.52%5/30/2025 (Estimated)VANIVivani Medical-$25.65M-$0.44N/AN/AN/AN/A-102.42%-49.21%N/AXAIRBeyond Air-$60.24M-$1.06N/AN/AN/A-1,730.00%-226.01%-109.75%6/23/2025 (Estimated)ZYXIZynex$9.73M-$0.2414.004.47N/A2.49%13.05%3.78%7/23/2025 (Estimated)Latest XAIR, NTRB, ZYXI, and VANI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025N/ANTRBNutriband-$0.13N/AN/AN/A$0.71 millionN/A5/12/2025Q1 2025VANIVivani Medical-$0.10-$0.11-$0.01-$0.11N/AN/A4/28/2025Q4 2025NTRBNutriband-$0.12-$0.18-$0.06-$0.51$0.71 million$0.64 million4/28/2025Q1 2025ZYXIZynex-$0.24-$0.33-$0.09-$0.33$30.83 million$26.58 million3/31/2025Q4 2024VANIVivani Medical-$0.10-$0.11-$0.01-$0.11N/AN/A3/11/2025Q4 2024ZYXIZynex$0.09-$0.02-$0.11-$0.02$53.65 million$45.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNTRBNutribandN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/AZYXIZynexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNTRBNutriband0.014.964.83VANIVivani MedicalN/A3.413.41XAIRBeyond AirN/A3.563.12ZYXIZynex1.663.943.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNTRBNutriband19.70%VANIVivani Medical6.78%XAIRBeyond Air31.50%ZYXIZynex29.68%Insider OwnershipCompanyInsider OwnershipNTRBNutriband54.09%VANIVivani Medical44.30%XAIRBeyond Air19.40%ZYXIZynex49.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNTRBNutriband1011.15 million5.10 millionNot OptionableVANIVivani Medical2059.24 million32.99 millionOptionableXAIRBeyond Air7086.37 million54.97 millionOptionableZYXIZynex77030.24 million15.25 millionOptionableXAIR, NTRB, ZYXI, and VANI HeadlinesRecent News About These CompaniesShareholders of Zynex, Inc. (ZYXI): Protect Your Rights Before May 19, 2025 - Contact Levi & KorsinskyMay 14 at 6:45 PM | accessnewswire.comZYXI Deadline: ZYXI Investors with Losses in Excess of $100K Have Opportunity to Lead Zynex, Inc. Securities Fraud LawsuitMay 14 at 6:18 PM | prnewswire.comZynex Submits 510(k) for NiCO™ CO-OximeterMay 14 at 5:42 PM | tipranks.comLevi & Korsinsky Urges Zynex, Inc. (ZYXI) Shareholders to Act Before Lead Plaintiff Deadline May 19, 2025May 14 at 4:30 PM | accessnewswire.comInvestor Lawsuit Accuses Medical Device Maker Zynex (ZYXI) of Inflating Revenue Through Excessive Shipments; Subsequent Earnings Report Reveals Significant Financial Strain– Hagens BermanMay 14 at 4:14 PM | globenewswire.comZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMay 14 at 4:00 PM | globenewswire.comShareholders of Zynex, Inc. (ZYXI): Protect Your Rights Before May 19, 2025 - Contact Levi & KorsinskyMay 14 at 3:30 PM | accessnewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ZynexMay 14 at 3:11 PM | globenewswire.comZynex, Inc. (ZYXI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitMay 14 at 1:04 PM | gurufocus.comZynex, Inc. (ZYXI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitMay 14 at 12:00 PM | prnewswire.comDid You Lose Money on Zynex, Inc. (ZYXI)? Levi & Korsinsky Urges Investors to Act Before May 19, 2025May 14 at 9:15 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Zynex, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZYXIMay 14 at 9:00 AM | accessnewswire.comZYXI Lawsuit Alert! Class Action Lawsuit Against Zynex, Inc.May 14 at 8:32 AM | tipranks.comZynex, Inc. (ZYXI) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before May 19, 2025May 14 at 7:15 AM | accessnewswire.comZYXI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Zynex, Inc. to Contact the Firm Today!May 14 at 7:00 AM | accessnewswire.comLevi & Korsinsky Reminds Zynex, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 19, 2025 – ZYXIMay 13 at 11:00 PM | accessnewswire.comLevi & Korsinsky Reminds Zynex, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 19, 2025 - ZYXIMay 13 at 9:45 PM | accessnewswire.comClass Action Filed Against Zynex, Inc. (ZYXI) - May 19, 2025 Deadline to Join - Contact Levi & KorsinskyMay 13 at 8:30 PM | accessnewswire.comInvestor Lawsuit Accuses Medical Device Maker Zynex (ZYXI) of Inflating Revenue Through Excessive Shipments; Subsequent Earnings Report Reveals Significant Financial Strain– Hagens BermanMay 13 at 8:10 PM | accessnewswire.comLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Zynex, Inc.(ZYXI) ShareholdersMay 13 at 7:00 PM | accessnewswire.comHC Wainwright Issues Negative Estimate for Zynex EarningsMay 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXAIR, NTRB, ZYXI, and VANI Company DescriptionsNutriband NASDAQ:NTRB$5.64 -0.09 (-1.57%) As of 04:00 PM EasternNutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.Vivani Medical NASDAQ:VANI$1.01 -0.04 (-3.81%) As of 04:00 PM EasternVivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.Beyond Air NASDAQ:XAIR$0.18 0.00 (-2.17%) As of 04:00 PM EasternBeyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.Zynex NASDAQ:ZYXI$2.10 -0.07 (-3.23%) As of 04:00 PM EasternZynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
